Intellia Therapeutics Inc
NTLA
Market Cap$1.22B
Close$
$-10.83
189.8% downside
Current Fair Value
189.8% downsideOvervalued by 189.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.22 Billion |
|---|---|
| Enterprise Value | $1.18 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.25 |
| Beta | 2.32 |
| Outstanding Shares | 103,732,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.45 |
|---|---|
| PEG | 7.89 |
| Price to Sales | - |
| Price to Book Ratio | 2.01 |
| Enterprise Value to Revenue | 22.37 |
| Enterprise Value to EBIT | -2.36 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus ?ik?nys . The company has partnerships with Novartis and Regeneron. Intellia Th...